Designing a vaccination strategy against dengue;Modelos para implementar a vacinação contra dengue

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 54, Issue SUPPL.18, 2012, Pages 18-21

  Amaku, Marcos ^a   Coudeville, Laurent ^b   Massad, Eduardo ^a,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SANOFI PASTEUR   (France)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE;

AGE; ARTICLE; BRAZIL; CALCULATION; DENGUE; HUMAN; IMMUNE RESPONSE; INFECTION RISK; MATHEMATICAL ANALYSIS; MAXIMUM LIKELIHOOD METHOD; MORTALITY; SEROCONVERSION; SEROPREVALENCE; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BRAZIL; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MIDDLE AGED; MODELS, THEORETICAL; SEROEPIDEMIOLOGIC STUDIES; VACCINATION; YOUNG ADULT;

EID: 84867121261     PISSN: 00364665     EISSN: 16789946     Source Type: Journal    
DOI: 10.1590/S0036-46652012000700008     Document Type: Article

References (16)

1. Plotkin SA. Vaccines, the fourth century. Clin Vaccine Immunol. 2009;16:1709-19.
2. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang, J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28:632-49.
3. Guy B, Almond J, Lang J. Dengue vaccine prospects: a step forward. Lancet. 2011;377(9763):381-2.
4. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavirusnaïve adults. J Infect Dis. 2010;201:370-7.
5. Tien NT, Luxemburger C, Toan NO, Pollissard-Gadroy L, Huong VT, Van Be P, et al. A prospective cohort study of dengue infection in schoolchildren in Long Xuyen, Viet Nam. Trans R Soc Trop Med Hyg. 2010;104;592-600.
6. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH. Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediat Infect Dis J. 2011;30:e9-e17.
7. Capending RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, et al. Liveattenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine. 2011;29:3863-72.
8. Durbin AP, Whitehead SS. Dengue vaccine candidates in development. Curr Top Microbiol Immunol. 2010;338:129-43.
9. Endy TP, Yoon IK, Mammen MP. Prospective cohort studies of dengue viral transmission and severity of disease. Curr Top Microbiol Immunol. 2010;338:1-13.
10. Massad E, Burattini MN, Azevedo Neto RS, Yang HM, Coutinho FA, Zanetta DM. A model-based design of a vaccination strategy against rubella in a non-immunized community of São Paulo State, Brazil. Epidemiol Infect. 1994;112:579-94.
11. Amaku M, Coutinho FA, Azevedo RS, Burattini MN, Lopez LF, Massad E. Vaccination against rubella: analysis of the temporal evolution of the age-dependent force of infection and the effects of different contact patterns. Phys Rev E Stat Nonlin Soft Matter Phys. 2003;67:051907.
12. Braga C, Luna CF, Martelli CM, de Souza WV, Cordeiro MT, Alexander N, et al. Seroprevalence and risk factors for dengue infection in socio-economically distinct areas of Recife, Brazil. Acta Trop. 2010;113:234-40.
13. Anderson RM, May RM. Infectious disease in humans: dynamics and control. Oxford: Oxford University Press; 1991.
14. Dietz K. The incidence of infectious disease under the influence of seasonal fluctuations. In: Lecture Notes in Biomathematics. New York: Springer-Verlag; 1976. v.11, p. 1-15.
15. Hethcote HW. Optimal ages of vaccination for measles. Math Biosci. 1988;89:29-52.
16. Van Panhuis W, Luxemburger C, Pengsaa K, Limkittikul K, Sabchareon A, Lang J, et al. Decay and persistence of maternal dengue antibodies among infants in Bangkok. Am J Trop Med Hyg. 2011;85:355-62.